Dr. Pinter-Brown on Treatment Expectations in CTCL
Lauren Pinter-Brown, MD
Published Online: Tuesday, April 2, 2013
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma (CTCL).
As with other oncologic conditions, if a patient is being treated with a drug and progresses, it is obvious that the drug is ineffective. In patients with CTCL, physicians have to be aware of the time to response for particular treatments, as they're not identical.
In the case of bexarotene, the time to response is four months, which causes physicians and patients to set appropriate expectations as the patient's condition will not worsen but it will not get better for many months. Fortunately, monitoring CTCL does not require scans or blood tests: physicians simply have to monitor skin lesions as time passes.
Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options
Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin’s lymphoma.